Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Drain fluid may hold key to immunotherapy response in gastroesophageal cancer

NCT ID NCT05338060

Knowledge-focused Sponsor: Inova Health Care Services Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study collected surgical drain fluid and blood from 10 patients who had surgery for stomach or esophageal cancer. Researchers analyzed these samples for molecular markers that might predict how well a patient would respond to immunotherapy. The goal was to establish a method for collecting and studying these fluids, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify which patients with gastroesophageal cancer are most likely to benefit from immunotherapy after surgery.
What could go wrong
This was a very small, early study (10 participants) focused on collecting samples, not testing a treatment. The findings may not lead to a usable test or apply to larger populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

10 people

The number who actually took part.

Started

Jan 2022

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult males and females at least 18 years of age undergoing esophagectomy or gastrectomy for gastroesophageal cancer

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing esophagectomy or gastrectomy for gastroesophageal cancer. * Adult males and females at least 18 years of age * Ability to complete testing in the protocol and attend study visits * Able and willing to consent to protocol * Adequate organ function Absolute Neutrophil Count (ANC) ≥1.5 x 103/μL Platelets ≥100 x 103/μL Hemoglobin \>9.0 g/dL Total Bilirubin (\</= 2.0 mg/dl at time of Y90 radioembolization) AST/ALT ≤5 x upper limit of normal Albumin \>3 g/dL Creatinine ≤1.5 mg/dL Exclusion Criteria: * Female patients who are pregnant or breast-feeding * Concomitant illness that would prevent adequate patient assessment or in the investigators' opinion pose an added risk for study participants. * Life-threatening intercurrent illness * Anticipated poor compliance * Prisoners or subjects who are involuntarily incarcerated * Persons with decisional incapacity/cognitive impairment * Any history or evidence of severe illness or any other condition that would make the patient, in the opinion of the investigator unsuitable for the study * Subject is enrolled in a separate interventional clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastroesophageal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastroesophageal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastroesophageal cancer

Contacts and locations

Locations

  • Inova Schar Cancer Institute

    Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.